Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1993 1
1995 1
1998 2
2001 4
2002 5
2003 9
2004 9
2005 11
2006 13
2007 6
2008 13
2009 6
2010 7
2011 11
2012 7
2013 13
2014 39
2015 50
2016 83
2017 87
2018 98
2019 133
2020 115
2021 143
2022 147
2023 146
2024 144
2025 145
2026 91

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,338 results

Results by year

Filters applied: . Clear all
Page 1
Targeting de novo purine biosynthesis for tuberculosis treatment.
Lamprecht DA, Wall RJ, Leemans A, Truebody B, Sprangers J, Fiogbe P, Davies C, Wetzel J, Daems S, Pearson W, Pillay V, Saylock S, Ricketts MD, Davis E, Huff A, Grell T, Lin S, Gerber M, Vos A, Dallow J, Willcocks SJ, Roubert C, Sans S, Desorme A, Chappat N, Ray A, Pereira Moraes M, Washington T, D'Erasmo H, Sancheti P, Everaerts M, Monshouwer M, Esquivias J, Larrouy-Maumus G, Draghia Akli R, Fletcher H, Pym AS, Aldridge BB, Sarathy JP, Clancy KW, Stoops B, Dhar N, Steyn AJC, Jackson P, Aguilar-Pérez C, Koul A. Lamprecht DA, et al. Nature. 2025 Aug;644(8075):214-220. doi: 10.1038/s41586-025-09177-7. Epub 2025 Jun 18. Nature. 2025. PMID: 40533558 Free PMC article.
Novel immunotherapeutics against LGR5 to target multiple cancer types.
Chen HC, Mueller N, Stott K, Kapeni C, Rivers E, Sauer CM, Beke F, Walsh SJ, Ashman N, O'Brien L, Rafati Fard A, Ghodsinia A, Li C, Joud F, Giger O, Zlobec I, Olan I, Aitken SJ, Hoare M, Mair R, Serrao E, Brenton JD, Garcia-Gimenez A, Richardson SE, Huntly B, Spring DR, Skjoedt MO, Skjødt K, de la Roche M, de la Roche M. Chen HC, et al. EMBO Mol Med. 2024 Sep;16(9):2233-2261. doi: 10.1038/s44321-024-00121-2. Epub 2024 Aug 21. EMBO Mol Med. 2024. PMID: 39169164 Free PMC article.
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy.
Lek A, Wong B, Keeler A, Blackwood M, Ma K, Huang S, Sylvia K, Batista AR, Artinian R, Kokoski D, Parajuli S, Putra J, Carreon CK, Lidov H, Woodman K, Pajusalu S, Spinazzola JM, Gallagher T, LaRovere J, Balderson D, Black L, Sutton K, Horgan R, Lek M, Flotte T. Lek A, et al. N Engl J Med. 2023 Sep 28;389(13):1203-1210. doi: 10.1056/NEJMoa2307798. N Engl J Med. 2023. PMID: 37754285 Free PMC article.
Structures, functions and adaptations of the human LINE-1 ORF2 protein.
Baldwin ET, van Eeuwen T, Hoyos D, Zalevsky A, Tchesnokov EP, Sánchez R, Miller BD, Di Stefano LH, Ruiz FX, Hancock M, Işik E, Mendez-Dorantes C, Walpole T, Nichols C, Wan P, Riento K, Halls-Kass R, Augustin M, Lammens A, Jestel A, Upla P, Xibinaku K, Congreve S, Hennink M, Rogala KB, Schneider AM, Fairman JE, Christensen SM, Desrosiers B, Bisacchi GS, Saunders OL, Hafeez N, Miao W, Kapeller R, Zaller DM, Sali A, Weichenrieder O, Burns KH, Götte M, Rout MP, Arnold E, Greenbaum BD, Romero DL, LaCava J, Taylor MS. Baldwin ET, et al. Nature. 2024 Feb;626(7997):194-206. doi: 10.1038/s41586-023-06947-z. Epub 2023 Dec 14. Nature. 2024. PMID: 38096902 Free PMC article.
Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.
Guirguis AA, Ofir-Rosenfeld Y, Knezevic K, Blackaby W, Hardick D, Chan YC, Motazedian A, Gillespie A, Vassiliadis D, Lam EYN, Tran K, Andrews B, Harbour ME, Vasiliauskaite L, Saunders CJ, Tsagkogeorga G, Azevedo A, Obacz J, Pilka ES, Carkill M, MacPherson L, Wainwright EN, Liddicoat B, Blyth BJ, Albertella MR, Rausch O, Dawson MA. Guirguis AA, et al. Cancer Discov. 2023 Oct 5;13(10):2228-2247. doi: 10.1158/2159-8290.CD-23-0007. Cancer Discov. 2023. PMID: 37548590
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.
Shneider NA, Harms MB, Korobeynikov VA, Rifai OM, Hoover BN, Harrington EA, Aziz-Zaman S, Singleton J, Jamil A, Madan VR, Lee I, Andrews JA, Smiley RM, Alam MM, Black LE, Shin M, Watts JK, Walk D, Newman D, Pascuzzi RM, Weber M, Neuwirth C, Da Cruz S, Soriano A, Lane R, Henry S, Mathews J, Jafar-Nejad P, Norris D, Rigo F, Brown RH, Miller S, Crean R, Bennett CF. Shneider NA, et al. Lancet. 2025 Jun 7;405(10494):2075-2086. doi: 10.1016/S0140-6736(25)00513-6. Epub 2025 May 22. Lancet. 2025. PMID: 40414239 Free PMC article.
Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment.
Shenton J, Bousnina I, Oropallo M, David R, Weir L, Baker TK, Dunmore HM, Villenave R, McElroy M, Pettersen B, Kokate T, Fuller CL, Homan KA, Hudry E, Wood C, Gunter S. Shenton J, et al. Drug Discov Today. 2025 Apr;30(4):104328. doi: 10.1016/j.drudis.2025.104328. Epub 2025 Mar 12. Drug Discov Today. 2025. PMID: 40086787 Free article. Review.
An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript.
Dindot SV, Christian S, Murphy WJ, Berent A, Panagoulias J, Schlafer A, Ballard J, Radeva K, Robinson R, Myers L, Jepp T, Shaheen H, Hillman P, Konganti K, Hillhouse A, Bredemeyer KR, Black L, Douville J; FIRE consortium; FIRE Consortium. Dindot SV, et al. Sci Transl Med. 2023 Mar 22;15(688):eabf4077. doi: 10.1126/scitranslmed.abf4077. Epub 2023 Mar 22. Sci Transl Med. 2023. PMID: 36947593
1,338 results